WHO guidelines on human genome editing: why countries need to follow them
By Sheetal Soni,
The Conversation
| 08. 22. 2021
The World Health Organisation (WHO) recently called on countries to stop any research that might lead to the birth of genetically edited human beings. The call was made with the release of the recommendations on human genome editing.
Human genome editing has great potential. It can improve human health and medicine by making changes to DNA in cells to correct, introduce or delete almost any DNA sequence which may cause disease. Other potential benefits include new ways to diagnose, treat and prevent genetic disorders, novel ways to treat infertility, increasing knowledge of human biology and contributing towards vaccine development.
The potential of this technology came into the spotlight in 2018 when Chinese scientist He Jiankui announced that he had edited the genomes of twin girls. His announcement was met with consternation among many scientists because it highlighted a significant gap in regulation.
In response, the WHO established a committee made up of a global multi-disciplinary panel of 18 experts. The committee was asked to develop standards for human genome editing.
After nearly three years the panel recently published...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
